Join to View Full Profile
605 Glenwood DrSuite 200Chattanooga, TN 37404
Phone+1 423-698-1844
Fax+1 423-624-2226
Dr. Daniel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 2002 - 2005- Duke University HospitalResidency, Internal Medicine, 1999 - 2002
Johns Hopkins University School of MedicineClass of 1999
Certifications & Licensure
GA State Medical License 2005 - 2027
TN State Medical License 2005 - 2027
NC State Medical License 1999 - 2006
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc, 2012, 2014-2017
- CMS Meaningful Use Stage 2 Certification ARIA Oncology Information System (for Medical Oncology), Varian Medical Systems, 2012, 2014-2017
- CMS Meaningful Use Stage 1 Certification ARIA oncology information system (for Medical Oncology), Varian Medical Systems, 2012, 2014-2017
Clinical Trials
- Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer Start of enrollment: 2009 Feb 01
- Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer Start of enrollment: 2011 Jan 11
- A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants Start of enrollment: 2013 Aug 01
Publications & Presentations
PubMed
- Patient-Reported Symptoms and Quality of Life With Sacituzumab Govitecan Versus Docetaxel in Metastatic NSCLC: The Phase 3, Randomized EVOKE-01 Trial.Niels Reinmuth, Sébastien Couraud, Luis Paz-Ares, Marina Chiara Garassino, Shobhit Baijal
JTO Clinical and Research Reports. 2026-02-01 - Impact of community recruitment and inclusion initiatives on enrollment in the biomarker-driven MyTACTIC trial.Richard M Zuniga, Ari VanderWalde, Lee S Schwartzberg, David R Spigel, Luke Passler
Future Oncology. 2026-01-01 - A rising tide lifts all boats in the personalized cancer care continuum for mNSCLC: bridging inequities in NGS fosters equity in targeted treatment.Victor T G Lin, Esprit Ma, Neha Jain, Zhiyu Xia, Danny Sheinson
The Oncologist. 2025-05-08
Journal Articles
- Overall Survival with Durvalumab After Chemoradiotherapy in Stage III NSCLCDavid R Spigel, Davey Daniel, Jhanelle E Gray, Augusto Villegas, Tarek Mekhail, Alberto Chiappori, The New England Journal of Medicine
Press Mentions
OneOncology Appoints Dr. Michael Byrne as Medical Director for Cellular TherapyJuly 7th, 2025- “Who Really Needs Chemotherapy” for Lung Cancer? New Test May Help Answer Key QuestionJuly 1st, 2025
- Cancer Biomarker Testing: Teaming with Physicians to Ensure Access EverywhereFebruary 7th, 2023
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
